Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Major Program

Supportive Care and Symptom Management

Status

Active, not recruiting

NCT ID

NCT04743934

This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.

Intervention

Androgen deprivation therapy, Flibanserin 100 MG, Placebo

Condition

Prostate Adenocarcinoma

Investigators

Andrew McDonald, MD

See list of participating sites